ClinicalTrials.gg
TerminatedNCT00145431Updated Feb 17, 2012

Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Subjects With A Genetic Cholesterol Disorder.

A Phase 3 interventional study of torcetrapib/atorvastatin and atorvastatin in Hyperlipoproteinemia Type III, sponsored by Pfizer. Terminated at 27 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-02-17.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
41
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The Torcetrapib project was terminated on December 2, 2006 due to safety findings.

To evaluate the efficacy and safety of the lipid drug torcetrapib/atorvastatin in subjects with a rare genetically known disorder of high cholesterol and triglyceride levels.

Read the detailed description

For additional information please call: 1-800-718-1021

02

Conditions studied

  • Hyperlipoproteinemia Type III
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Familial Dysbetalipoproteinemia (Fredrickson Type III hyperlipoproteinemia)

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant or lactating, or planning to become pregnant.
  • Subjects with a clinically indicated need for statin (HMG-CoA reductase inhibitor) therapy other than atorvastatin or other concomitant therapy with known lipid altering effects on LDL-C and HDL-C including fibrates and nicotinic acid
  • Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors
  • Subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluation of response, or render unlikely that the subject would complete the study
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double
Enrollment
41 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Change in LDL-C and non-HDL-C levels.

Secondary outcomes

  1. Changes in other lipid and biomarker variable levels.

07

Study locations

27 sites
  • Pfizer Investigational Site
    Anaheim, California 92804, United States
  • Pfizer Investigational Site
    Huntington Beach, California 92648, United States
  • Pfizer Investigational Site
    Orange, California 92868, United States
  • Pfizer Investigational Site
    Pacific Palisades, California 90272, United States
  • Pfizer Investigational Site
    Studio City, California 91604, United States
  • Pfizer Investigational Site
    Tustin, California 92780, United States
  • Pfizer Investigational Site
    Hollywood, Florida 33021, United States
  • Pfizer Investigational Site
    Longwood, Florida 32779, United States
  • Pfizer Investigational Site
    Tripler Army Medical Center, Hawaii 96859-5000, United States
  • Pfizer Investigational Site
    Scarborough, Maine 04074, United States
  • Pfizer Investigational Site
    Portage, Michigan 49002, United States
  • Pfizer Investigational Site
    Portage, Michigan 49024, United States
  • Pfizer Investigational Site
    Olive Branch, Mississippi 38654, United States
  • Pfizer Investigational Site
    Rochester, New York 14618, United States
  • Pfizer Investigational Site
    Syracuse, New York 13210, United States
  • Pfizer Investigational Site
    West Seneca, New York 14224, United States
  • Pfizer Investigational Site
    Sellersville, Pennsylvania 18960, United States
  • Pfizer Investigational Site
    Greer, South Carolina 29651, United States
  • Pfizer Investigational Site
    Memphis, Tennessee 38105, United States
  • Pfizer Investigational Site
    Salt Lake City, Utah 84108, United States
  • Pfizer Investigational Site
    Seattle, Washington 98104, United States
  • Pfizer Investigational Site
    Madison, Wisconsin 53719, United States
  • Pfizer Investigational Site
    London, Ontario N6A 5K8, Canada
  • Pfizer Investigational Site
    Chicoutimi, Quebec G7H 5H6, Canada
  • Pfizer Investigational Site
    Montreal, Quebec H1T 1C8, Canada
  • Pfizer Investigational Site
    Montreal, Quebec H2W 1R7, Canada
  • Pfizer Investigational Site
    Quebec, G1V 4M6, Canada
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2005, a primary completion of Dec 2006 and a completion of Dec 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2005
First posted
Sep 5, 2005
Start
Mar 2005
Primary completionActual
Dec 2006
CompletionActual
Dec 2006
Results delay requested
Feb 15, 2012
Last update
Feb 17, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00145431
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Sep 5, 2005
Start date
Mar 2005
Primary completion
Dec 2006
Completion
Dec 2006
Last update
Feb 17, 2012

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Torcetrapib · Atorvastatin · Fenofibrate

Start the discussion